The Royal Orthopaedic Hospital Oncology Service, Bristol Road South, Birmingham, B31 2AP, UK.
Eur Spine J. 2010 Jul;19(7):1189-94. doi: 10.1007/s00586-009-1270-8. Epub 2010 Jan 14.
To investigate the outcome of our management of patients with giant cell tumour of the sacrum and draw lessons from this. A retrospective review of medical records and scans for all patients treated at our unit over the past 20 years with a giant cell tumour of the sacrum. Of the 517 patients treated at our unit for giant cell tumour over the past 20 years, only 9 (1.7%) had a giant cell tumour in the sacrum. Six were female, three male with a mean age of 34 (range 15-52). All, but two tumours involved the entire sacrum and there was only one purely distal to S3. The mean size was 10 cm and the most common symptom was back or buttock pain. Five had abnormal neurology at diagnosis, but only one presented with cauda equina syndrome. The first four patients were treated by curettage alone, but two patients had intraoperative cardiac arrests and although both survived all subsequent curettages were preceded by embolisation of the feeding vessels. Of the seven patients who had curettage, three developed local recurrence, but all were controlled with a combination of further embolisation, surgery or radiotherapy. One patient elected for treatment with radiotherapy and another had excision of the tumour distal to S3. All the patients are alive and only two patients have worse neurology than at presentation, one being impotent and one with stress incontinence. Three patients required spinopelvic fusion for sacral collapse. All patients are mobile and active at a follow-up between 2 and 21 years. Giant cell tumour of the sacrum can be controlled with conservative surgery rather than subtotal sacrectomy. The excision of small distal tumours is the preferred option, but for larger and more extensive tumours conservative management may well avoid morbidity whilst still controlling the tumour. Embolisation and curettage are the preferred first option with radiotherapy as a possible adjunct. Spinopelvic fusion may be needed when the sacrum collapses.
为了调查我们对骶骨巨细胞瘤患者的治疗结果,并从中吸取经验教训。回顾性分析了过去 20 年来在我们单位接受治疗的所有骶骨巨细胞瘤患者的病历和扫描结果。在过去 20 年中,我们单位共治疗了 517 例骶骨巨细胞瘤患者,其中只有 9 例(1.7%)为骶骨巨细胞瘤。6 例为女性,3 例为男性,平均年龄为 34 岁(范围 15-52 岁)。除了两个肿瘤完全位于骶骨外,所有肿瘤均累及整个骶骨,只有一个肿瘤纯粹位于 S3 以下。肿瘤平均大小为 10cm,最常见的症状是背部或臀部疼痛。诊断时 5 例有神经功能异常,但只有 1 例出现马尾综合征。前 4 例患者仅接受刮除术治疗,但有 2 例患者在术中发生心脏骤停,尽管 2 例患者均存活,但所有后续的刮除术均在肿瘤供血血管栓塞后进行。在接受刮除术的 7 例患者中,有 3 例出现局部复发,但均通过进一步栓塞、手术或放疗得到控制。1 例患者选择接受放疗,另 1 例患者接受 S3 以下肿瘤切除。所有患者均存活,仅有 2 例患者的神经功能比就诊时更差,1 例为阳痿,1 例为压力性尿失禁。3 例患者因骶骨塌陷而行脊柱骨盆融合术。所有患者在随访 2 至 21 年期间均保持活动能力,生活质量良好。骶骨巨细胞瘤可通过保守手术而非次全骶骨切除术来控制。对于较小的远端肿瘤,首选切除;但对于较大和更广泛的肿瘤,保守治疗可能可以避免并发症,同时控制肿瘤。栓塞和刮除术是首选的初始治疗方法,放疗可作为辅助手段。当骶骨塌陷时,可能需要进行脊柱骨盆融合术。